Stereochemistry | ABSOLUTE |
Molecular Formula | C21H24N2O5S2 |
Molecular Weight | 448.556 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CN1C[C@H](SC[C@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)C1=O)C3=CC=CS3
InChI
InChIKey=KZVWEOXAPZXAFB-BQFCYCMXSA-N
InChI=1S/C21H24N2O5S2/c24-19(25)12-23-11-18(17-7-4-10-29-17)30-13-16(20(23)26)22-15(21(27)28)9-8-14-5-2-1-3-6-14/h1-7,10,15-16,18,22H,8-9,11-13H2,(H,24,25)(H,27,28)/t15-,16-,18-/m0/s1
Originator
Approval Year
PubMed
Sample Use Guides
A tablet containing 2 mg of temocapril hydrochloride was administered once a day in the morning, and the monitoring term was for 16 weeks.
Route of Administration:
Oral
A force of 1.0 g was applied, and the strips were allowed to equilibrate for 90 min. Aortic strips were exposed to 30 nM of angiotensin I (AI), which produced contractions approximately equal to 90% of the maximum response. After three successive contractions of equal size had been obtained, test drugs (CS-622 diacid) was added to the bath. Contractile responses to AI in the presence of a test drug were compared with control responses before the drug was added. The concentration of the drug was increased in a cumulative manner by a ratio of 3 at a 10 min interval to construct a concentration
inhibition curve. The IC50 value was determined as the concentration inhibiting by 50% the response to AI